Stay updated with breaking news from Lee Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
BASEL (dpa-AFX) - Swiss pharma giant Novartis AG (NVS) on Wednesday announced positive data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah in patients with relapsed or